ReviewMolecular biology reports2026
A-to-I mRNA editing: Why not simply incorporate inosine during mRNA synthesis?
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Adenosine-to-inosine (A-to-I) mRNA editing, catalyzed by ADAR enzymes, is a pervasive post-transcriptional mechanism that diversifies transcriptomes and protects against innate immune activation. This study asks a fundamental "why not" question: why organisms edit adenosine to inosine rather than directly incorporating inosine during mRNA synthesis? We argue that while inosine triphosphate (ITP) could theoretically serve as a transcriptional substrate, its biochemical, regulatory, and evolutionary constraints potentially make this mechanism less feasible. Direct inosine incorporation might replace guanosine instead of adenosine, disrupt editing precision, abolish transcriptomic diversity, and reduce transcriptional/translational efficiency. The universal ITP-to-IMP pathway might reflect the evolutionary pressure to prevent inosine accumulation. Thus, A-to-I RNA editing seems to be a safer, spatially confined solution that reconciles molecular flexibility with genomic fidelity. Understanding why life edits rather than encodes inosine reveals the deep evolutionary logic guiding RNA modification systems.
Indexed as
Identifiers
42507190What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.